ChiCTR2200058839
Untitled Trial
Evaluation the efficacy and safety of reduced-dose adalimumab in Chinese patients with rheumatoid arthritis (RA): A Multicenter, prospective, parallel-group, real-world study
The Second Affiliated Hospital Of Nanchang University·Phase 4·Chinese Clinical Trial RegistryNot yet recruiting
View on Chinese Clinical Trial Registry →Study focus
- Disease/Condition
- Rheumatoid arthritis
Sponsor & location
- Primary sponsor
- The Second Affiliated Hospital Of Nanchang University
- Funder
- Biothera Solutions, formerly as Sinoasis Pharma, Ltd.
- Location
- China
Timeline & enrollment
- Phase
- Phase 4
- Start date
- N/A
- End date
- Apr 30, 2024
ICD-10 classifications
Rheumatoid arthritis, unspecifiedOther rheumatoid arthritisOther specified rheumatoid arthritisRheumatoid arthritis with involvement of other organs and systemsSeronegative rheumatoid arthritis
Data source
- Registry
- Chinese Clinical Trial Registry
- Trial ID
- ChiCTR2200058839
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for ChiCTR2200058839 through Pure Global AI's free database. This Phase 4 trial is sponsored by The Second Affiliated Hospital Of Nanchang University and is currently Not yet recruiting. The study focuses on Rheumatoid arthritis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.